Qin-Wen Liu
Overview
Explore the profile of Qin-Wen Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Q, Fan Q, Chen J, Liu J, Li Y, Luo Q, et al.
Adv Sci (Weinh)
. 2025 Jan;
12(10):e2413174.
PMID: 39813169
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis. The natural compound pristimerin has shown promising anti-tumor effect. Here, it is found that pristimerin significantly...
2.
Wang N, Jiang Q, Xie L, Cheng B, Liu Q, Jiang R
Andrology
. 2023 May;
12(1):222-230.
PMID: 37222247
Background: It has been shown that methylation in the promoter region of eNOS can downregulate eNOS expression resulting in the endothelial dysfunction. However, it is unclear whether low androgen levels...
3.
Deng C, Zhang G, Liu Q, Xu J, Liu Z, Yang J, et al.
Cancer Res
. 2023 Mar;
83(11):1851-1865.
PMID: 36912612
Metastatic cancer cells upregulate ANO1 to activate cell-intrinsic and -extrinsic mechanisms that alter cholesterol metabolism and stimulate fibroblasts, which can be targeted with ANO1 inhibitors to inhibit metastatic growth. See...
4.
Ou Z, Zhu L, Liu Q, Jiang J, Jiang R
Andrologia
. 2022 May;
54(8):e14477.
PMID: 35596534
The exact mechanism by which testosterone deficiency causes ED has not yet been elucidated. TRPC is involved in the process of smooth muscle cell contraction and relaxation. The effect of...
5.
Liu Q, He Y, Xu W
Exp Mol Med
. 2022 Mar;
54(3):216-225.
PMID: 35352001
Cancer is one of the most difficult diseases in human society. Therefore, it is urgent for us to understand its pathogenesis and improve the cure rate. Exosomes are nanoscale membrane...
6.
Tan X, He Y, Huang Y, Zheng C, Li J, Liu Q, et al.
MedComm (2020)
. 2021 Nov;
2(3):453-466.
PMID: 34766155
Colorectal cancer (CRC) is one of the most common malignancies currently. Despite advances in drug development, the survival and response rates in CRC patients are still poor. In our previous...
7.
Liu Q, Yang Z, Jiang J, Jiang R
Andrology
. 2021 Jan;
9(1):342-351.
PMID: 33507631
Background: Type 5 phosphodiesterase inhibitor (PDE5I) has become the first-line treatment for erectile dysfunction (ED). However, its effective rate for hypertension ED is only 60%-70%. How to improve the efficacy...
8.
Hong P, Liu Q, Xie Y, Zhang Q, Liao L, He Q, et al.
Cell Death Dis
. 2020 Jul;
11(7):524.
PMID: 32655130
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors with poor survival. It is urgent to search for new efficient drugs with good stability and safety...